RxDoctor Payments Data

Charles Kulwin, MD

Neurological Surgery · Carmel, INNPI 1619294600

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (39.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by NICO Corporation at 44.4% of the total. Reporting peaked in 2019 at $3,974 and has fallen 92.4% since, to $302 in 2025.

$10,072in general payments, 2019–2025

Across 52 payments — averaging $193.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • NICO Corporation$4K
  • Medtronic$4K
  • Stryker$1K
  • DJO, LLC$173
  • Johnson & Johnson$81
  • Orthofix Medical, Inc.$40
  • plus $95 from 5 others
$1,200in research payments, 2019–2025

Across 1 payment — averaging $1199.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biogen$1K

What the payments were for

  • Consulting fees$2,90029%
  • Speaking & faculty fees$4,00040%
  • Travel & lodging$2,23122%
  • Food & beverage$9219%
  • Education$200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,072 in reported general payments places this provider in the 70th percentile of 112 neurological surgery providers in Indiana.

See all neurological surgery providers in Indiana

Medicare billing

Part B allowed, 2024
$131,861
Medicare patients
227
Services billed
448

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Levetiracetam43$535
Gabapentin31$305
Dexamethasone19$248
Famotidine13$124

Paid to pharmacies, not to this prescriber.

Other neurological surgery in Carmel

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →